Effects of Estrogen Metabolite 2-Methoxyestradiol on Tumor Suppressor Protein p53 and Proliferation of Breast Cancer Cells

References

• Agrawal, S.S. and Alvin Jose, M. (2010) Roxatidine, an H(2) receptor blocker, is an estrogenic compound–experimental evidence. Syst Biol Reprod Med 56:286–291.
   PubMed Web of Science ®Google Scholar
• Attalla, H., Makela, T.P., Adlercreutz, H. and Andersson, L.C. (1996) 2-Methoxyestradiol arrests cells in mitosis without depolymerizing tubulin. Biochem Biophys Res Commun 228:467–473.
   PubMed Web of Science ®Google Scholar
• Azab, S.S., Salama, S.A., Abdel-Naim, A.B., Khalifa, A.E., El-Demerdash, E. and Al-Hendy, A. (2009) 2-Methoxyestradiol and multidrug resistance: can 2-methoxyestradiol chemosensitize resistant breast cancer cells? Breast Cancer Res Treat 113:9–19.
   Google Scholar
• Benninghoff, J., Kartarius, S., Teleb, Z., Selter, H., Unteregger, G., Zwergel, T., (1999) Two different forms of p53 localized differently within cells of urogenital tumours. Cancer Lett 144:55–64.
   PubMedGoogle Scholar
• Bradford, M.M. (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248–254.
   PubMed Web of Science ®Google Scholar
• Cho, Y., Gorina, S., Jeffrey, P.D. and Pavletich, N.P. (1994) Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. Science 265:346–355.
   PubMed Web of Science ®Google Scholar
• Cushman, M., He, H.M., Katzenellenbogen, J.A., Lin, C.M. and Hamel, E. (1995) Synthesis, antitubulin and antimitotic activity, and cytotoxicity of analogs of 2-methoxyestradiol, an endogenous mammalian metabolite of estradiol that inhibits tubulin polymerization by binding to the colchicine binding site. J Med Chem 38:2041–2049.
   PubMed Web of Science ®Google Scholar
• D'Amato, R.J., Lin, C.M., Flynn, E., Folkman, J. and Hamel, E. (1994) 2-Methoxyestradiol, an endogenous mammalian metabolite, inhibits tubulin polymerization by interacting at the colchicine site. Proc Natl Acad Sci USA 91:3964–3968.
   PubMed Web of Science ®Google Scholar
• Depalo, R., Lorusso, F., Bettocchi, S., Selvaggi, L., Cavallini, A., Valentini, A.M., (2009) Assessment of estrogen receptors and apoptotic factors in cryopreserved human ovarian cortex. Syst Biol Reprod Med 55:236–243.
   PubMed Web of Science ®Google Scholar
• Dinda, S., Kodali-Gali, S., Sevilla, L., Burkley, M., Hurd, C. and Moudgil, V.K. (1997) Inhibition of proliferation of T47D human breast cancer cells: alterations in progesterone receptor and p53 tumor suppressor protein. Mol Cell Biochem 175:81–89.
   PubMedGoogle Scholar
• Dinda, S., Sanchez, A. and Moudgil, V. (2002) Estrogen-like effects of thyroid hormone on the regulation of tumor suppressor proteins, p53 and retinoblastoma, in breast cancer cells. Oncogene 21:761–768.
   PubMed Web of Science ®Google Scholar
• Dinda, S., Sanchez, A. and Moudgil, V.K. (2010) Effects of LY117018 (a SERM analog of raloxifene) on tumor suppressor proteins and proliferation of breast cancer cells. Horm Mol Biol Clin Investig 2:211–217.
   PubMedGoogle Scholar
• Donehower, L.A. and Bradley, A. (1993) The tumor suppressor p53. Biochim Biophys Acta 1155:181–205.
   PubMed Web of Science ®Google Scholar
• El-Deiry, W.S., Tokino, T., Velculescu, V.E., Levy, D.B., Parsons, R., Trent, J.M., (1993) WAF1, a potential mediator of p53 tumor suppression. Cell 75:817–825.
   PubMed Web of Science ®Google Scholar
• Erster, S., Mihara, M., Kim, R.H., Petrenko, O. and Moll, U.M. (2004) In vivo mitochondrial p53 translocation triggers a rapid first wave of cell death in response to DNA damage that can precede p53 target gene activation. Mol Cell Biol 24:6728–6741.
   PubMed Web of Science ®Google Scholar
• Fotsis, T., Zhang, Y., Pepper, M.S., Adlercreutz, H., Montesano, R., Nawroth, P.P., (1994) The endogenous oestrogen metabolite 2-methoxyoestradiol inhibits angiogenesis and suppresses tumour growth. Nature 368:237–239.
   PubMed Web of Science ®Google Scholar
• Fuchs, S.Y., Adler, V., Buschmann, T., Wu, X. and Ronai, Z. (1998a) Mdm2 association with p53 targets its ubiquitination. Oncogene 17:2543–2547.
   PubMedGoogle Scholar
• Fuchs, S.Y., Adler, V., Buschmann, T., Yin, Z., Wu, X., Jones, S.N., (1998b) JNK targets p53 ubiquitination and degradation in nonstressed cells. Genes Dev 12:2658–2663.
   PubMed Web of Science ®Google Scholar
• Fuchs, S.Y., Adler, V., Pincus, M.R., and Ronai, Z. (1998c) MEKK1/JNK signaling stabilizes and activates p53. Proc Natl Acad Sci USA 95:10541–10546.
   PubMed Web of Science ®Google Scholar
• Fukui, M. and Zhu, B.T. (2009) Mechanism of 2-methoxyestradiol-induced apoptosis and growth arrest in human breast cancer cells. Mol Carcinog 48:66–78.
   PubMedGoogle Scholar
• Giannakakou, P., Robey, R., Fojo, T. and Blagosklonny, M.V. (2001) Low concentrations of paclitaxel induce cell type-dependent p53, p21 and G1/G2 arrest instead of mitotic arrest: molecular determinants of paclitaxel-induced cytotoxicity. Oncogene 20:3806–3813.
   PubMed Web of Science ®Google Scholar
• Grover, R., Candeias, M.M., Fahraeus, R. and Das, S. (2009) p53 and little brother p53/47: linking IRES activities with protein functions. Oncogene 28:2766–2772.
   PubMed Web of Science ®Google Scholar
• Halaby, M.J. and Yang, D.Q. (2007) p53 translational control: a new facet of p53 regulation and its implication for tumorigenesis and cancer therapeutics. Gene 395:1–7.
   PubMed Web of Science ®Google Scholar
• Hamel, E., Lin, C.M., Flynn, E. and D'Amato, R.J. (1996) Interactions of 2-methoxyestradiol, an endogenous mammalian metabolite, with unpolymerized tubulin and with tubulin polymers. Biochemistry 35:1304–1310.
   PubMed Web of Science ®Google Scholar
• Han, G.Z., Liu, Z.J., Shimoi, K. and Zhu, B.T. (2005) Synergism between the anticancer actions of 2-methoxyestradiol and microtubule-disrupting agents in human breast cancer. Cancer Res 65:387–393.
   PubMed Web of Science ®Google Scholar
• Haupt, Y., Maya, R., Kazaz, A. and Oren, M. (1997) Mdm2 promotes the rapid degradation of p53. Nature 387:296–299.
   PubMed Web of Science ®Google Scholar
• Hollstein, M., Sidransky, D., Vogelstein, B. and Harris, C.C. (1991) p53 mutations in human cancers. Science 253:49–53.
   PubMed Web of Science ®Google Scholar
• Horky, M., Wurzer, G., Kotala, V., Anton, M., Vojtesek, B., Vacha, J., (2001) Segregation of nucleolar components coincides with caspase-3 activation in cisplatin-treated HeLa cells. J Cell Sci 114:663–670.
   PubMed Web of Science ®Google Scholar
• Hupp, T.R., Meek, D.W., Midgley, C.A. and Lane, D.P. (1992) Regulation of the specific DNA binding function of p53. Cell 71:875–886.
   PubMed Web of Science ®Google Scholar
• Hurd, C., Khattree, N., Alban, P., Nag, K., Jhanwar, S.C., Dinda, S., (1995) Hormonal regulation of the p53 tumor suppressor protein in T47D human breast carcinoma cell line. J Biol Chem 270:28507–28510.
   PubMed Web of Science ®Google Scholar
• Hurd, C., Nag, K., Khattree, N., Alban, P., Dinda, S. and Moudgil, V.K. (1999) Agonist and antagonist-induced qualitative and quantitative alterations of progesterone receptor from breast cancer cells. Mol Cell Biochem 199:49–56.
   PubMedGoogle Scholar
• Karni-Schmidt, O., Friedler, A., Zupnick, A., McKinney, K., Mattia, M., Beckerman, R., (2007) Energy-dependent nucleolar localization of p53 in vitro requires two discrete regions within the p53 carboxyl terminus. Oncogene 26:3878–3891.
   PubMedGoogle Scholar
• Karni-Schmidt, O., Zupnick, A., Castillo, M., Ahmed, A., Matos, T., Bouvet, P., (2008) p53 is localized to a sub-nucleolar compartment after proteasomal inhibition in an energy-dependent manner. J Cell Sci 121:4098–4105.
   PubMedGoogle Scholar
• Klibanov, S.A., O'Hagan, H.M. and Ljungman, M. (2001) Accumulation of soluble and nucleolar-associated p53 proteins following cellular stress. J Cell Sci 114:1867–1873.
   PubMedGoogle Scholar
• Kodali, S., Burkley, M., Nag, K., Taylor, R.C. and Moudgil, V.K. (1994) Taxol and cisplatin inhibit proliferation of T47D human breast cancer cells. Biochem Biophys Res Commun 202:1413–1419.
   PubMedGoogle Scholar
• Latonen, L., Kurki, S., Pitkanen, K. and Laiho, M. (2003) p53 and MDM2 are regulated by PI-3-kinases on multiple levels under stress induced by UV radiation and proteasome dysfunction. Cell Signal 15:95–102.
   PubMedGoogle Scholar
• LaVallee, T.M., Zhan, X.H., Herbstritt, C.J., Kough, E.C., Green, S.J. and Pribluda, V.S. (2002) 2-Methoxyestradiol inhibits proliferation and induces apoptosis independently of estrogen receptors alpha and beta. Cancer Res 62:3691–3697.
   PubMed Web of Science ®Google Scholar
• Lee, L.F., Li, G., Templeton, D.J. and Ting, J.P. (1998) Paclitaxel (Taxol)-induced gene expression and cell death are both mediated by the activation of c-Jun NH2-terminal kinase (JNK/SAPK). J Biol Chem 273:28253–28260.
   PubMed Web of Science ®Google Scholar
• Liu, Z.J., Lee, W.J. and Zhu, B.T. (2005) Selective insensitivity of ZR-75-1 human breast cancer cells to 2-methoxyestradiol: evidence for type II 17beta-hydroxysteroid dehydrogenase as the underlying cause. Cancer Res 65:5802–5811.
   PubMedGoogle Scholar
• Liu, Z.J. and Zhu, B.T. (2004) Concentration-dependent mitogenic and antiproliferative actions of 2-methoxyestradiol in estrogen receptor-positive human breast cancer cells. J Steroid Biochem Mol Biol 88:265–275.
   PubMed Web of Science ®Google Scholar
• Lottering, M.L., Haag, M. and Seegers, J.C. (1992) Effects of 17 beta-estradiol metabolites on cell cycle events in MCF-7 cells. Cancer Res 52:5926–5932.
   PubMed Web of Science ®Google Scholar
• Mabjeesh, N.J., Escuin, D., LaVallee, T.M., Pribluda, V.S., Swartz, G.M., Johnson, M.S., (2003) 2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF. Cancer Cell 3:363–375.
   PubMed Web of Science ®Google Scholar
• Maggi, L.B. Jr. and Weber, J.D. (2005) Nucleolar adaptation in human cancer. Cancer investigation 23:599–608.
   PubMed Web of Science ®Google Scholar
• Mannisto, P.T. and Kaakkola, S. (1999) Catechol-O-methyltransferase (COMT): biochemistry, molecular biology, pharmacology, and clinical efficacy of the new selective COMT inhibitors. Pharmacol Rev 51:593–628.
   PubMed Web of Science ®Google Scholar
• Martin, M.B., Angeloni, S.V., Garcia-Morales, P., Sholler, P.F., Castro-Galache, M.D., Ferragut, J.A., (2004) Regulation of estrogen receptor-alpha expression in MCF-7 cells by taxol. J Endocrinol 180:487–496.
   PubMed Web of Science ®Google Scholar
• Miglietta, A., Panno, M.L., Bozzo, F., Gabriel, L. and Bocca, C. (2004) Insulin can modulate MCF-7 cell response to paclitaxel. Cancer Lett 209:139–145.
   PubMed Web of Science ®Google Scholar
• Milne, D.M., Campbell, L.E., Campbell, D.G. and Meek, D.W. (1995) p53 is phosphorylated in vitro and in vivo by an ultraviolet radiation-induced protein kinase characteristic of the c-Jun kinase, JNK1. J Biol Chem 270:5511–5518.
   PubMed Web of Science ®Google Scholar
• Miyashita, T. and Reed, J.C. (1995) Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 80:293–299.
   PubMed Web of Science ®Google Scholar
• Moudgil, V.K., Dinda, S., Khattree, N., Jhanwar, S., Alban, P. and Hurd, C. (2001) Hormonal regulation of tumor suppressor proteins in breast cancer cells. J Steroid Biochem Mol Biol 76:105–117.
   PubMed Web of Science ®Google Scholar
• Mueck, A.O. and Seeger, H. (2010) 2-Methoxyestradiol–Biology and mechanism of action. Steroids 75:625–631.
   PubMed Web of Science ®Google Scholar
• Mukhopadhyay, T. and Roth, J.A. (1997) Induction of apoptosis in human lung cancer cells after wild-type p53 activation by methoxyestradiol. Oncogene 14:379–384.
   PubMed Web of Science ®Google Scholar
• Nandi, S., Guzman, R.C. and Yang, J. (1995) Hormones and mammary carcinogenesis in mice, rats, and humans: a unifying hypothesis. Proc Natl Acad Sci USA 92:3650–3657.
   PubMed Web of Science ®Google Scholar
• Nigro, J.M., Baker, S.J., Preisinger, A.C., Jessup, J.M., Hostetter, R., Cleary, K., (1989) Mutations in the p53 gene occur in diverse human tumour types. Nature 342:705–708.
   PubMed Web of Science ®Google Scholar
• Noguchi, K., Kitanaka, C., Yamana, H., Kokubu, A., Mochizuki, T. and Kuchino, Y. (1999) Regulation of c-Myc through phosphorylation at Ser-62 and Ser-71 by c-Jun N-terminal kinase. J Biol Chem 274:32580–32587.
   PubMed Web of Science ®Google Scholar
• Pokrovskaja, K., Mattsson, K., Kashuba, E., Klein, G., and Szekely, L. (2001) Proteasome inhibitor induces nucleolar translocation of Epstein-Barr virus-encoded EBNA-5. J Gen Virol 82:345–358.
   PubMedGoogle Scholar
• Pribluda, V.S., Gubish, E.R., Jr., Lavallee, T.M., Treston, A., Swartz, G.M. and Green, S.J. (2000) 2-Methoxyestradiol: an endogenous antiangiogenic and antiproliferative drug candidate. Cancer Metastasis Rev 19:173–179.
   PubMed Web of Science ®Google Scholar
• Riley, T., Sontag, E., Chen, P. and Levine, A. (2008) Transcriptional control of human pp53–regulated genes. Nat Rev Mol Cell Biol 9:402–412.
   PubMed Web of Science ®Google Scholar
• Rubbi, C.P. and Milner, J. (2000) Non-activated p53 co-localizes with sites of transcription within both the nucleoplasm and the nucleolus. Oncogene 19:85–96.
   PubMed Web of Science ®Google Scholar
• Seegers, J.C., Aveling, M.L., Van Aswegen, C.H., Cross, M., Koch, F. and Joubert, W.S. (1989) The cytotoxic effects of estradiol-17 beta, catecholestradiols and methoxyestradiols on dividing MCF-7 and HeLa cells. J Steroid Biochem 32:797–809.
   PubMedGoogle Scholar
• Seegers, J.C., Lottering, M.L., Grobler, C.J., van Papendorp, D.H., Habbersett, R.C., Shou, Y., (1997) The mammalian metabolite, 2-methoxyestradiol, affects P53 levels and apoptosis induction in transformed cells but not in normal cells. J Steroid Biochem Mol Biol 62:253–267.
   PubMedGoogle Scholar
• Shimada, K., Nakamura, M., Ishida, E., Kishi, M. and Konishi, N. (2003) Roles of p38- and c-jun NH2-terminal kinase-mediated pathways in 2-methoxyestradiol-induced p53 induction and apoptosis. Carcinogenesis 24:1067–1075.
   PubMed Web of Science ®Google Scholar
• Van Zijl, C., Lottering, M.L., Steffens, F. and Joubert, A. (2008) In vitro effects of 2-methoxyestradiol on MCF-12A and MCF-7 cell growth, morphology and mitotic spindle formation. Cell Biochem Funct 26:632–642.
   PubMedGoogle Scholar
• Vijayanathan, V., Venkiteswaran, S., Nair, S.K., Verma, A., Thomas, T.J., Zhu, B.T., (2006) Physiologic levels of 2-methoxyestradiol interfere with nongenomic signaling of 17beta-estradiol in human breast cancer cells. Clin Cancer Res 12:2038–2048.
   PubMedGoogle Scholar
• Vogelstein, B., Lane, D. and Levine, A.J. (2000) Surfing the p53 network. Nature 408:307–310.
   PubMed Web of Science ®Google Scholar
• Wesierska-Gadek, J., Schloffer, D., Kotala, V. and Horky, M. (2002) Escape of p53 protein from E6-mediated degradation in HeLa cells after cisplatin therapy. Int J Cancer 101:128–136.
   PubMedGoogle Scholar